Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients

Gastroenterology

Volumn 138, Issue 3, 2010, Pages 913-921

  Reesink, Henk W ^a   Fanning, Gregory C ^b   Farha, Khalid Abou ^c   Weegink, Christine ^a   Van Vliet, André ^c   van 't Klooster, Gerben ^b   Lenz, Oliver ^b   Aharchi, Fatima ^b   Mariën, Kris ^b   Van Remoortere, Pieter ^b   de Kock, Herman ^b   Broeckaert, Fabrice ^b   Meyvisch, Paul ^b   Van Beirendonck, Els ^b   Simmen, Kenneth ^b   Verloes, René ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Tibotec Pharmaceuticals Ltd   (Ireland)

^c PRA Health Sciences   (Netherlands)

Author keywords

HCV; Phase 1 Study; Protease Inhibitor; TMC435

Indexed keywords

ANTIVIRUS AGENT; PLACEBO; TMC 435350; VIRUS RNA;

ABDOMINAL DISEASE; ABDOMINAL DISTENTION; ABDOMINAL PAIN; ADULT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; PHASE 1 CLINICAL TRIAL; PHOTOSENSITIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 77449158033     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2009.10.033     Document Type: Article

References (22)

1. WHO. Hepatitis C, fact sheet No. 164, 2000 (2000), World Health Organization, Geneva
2. Micallef J.M., Kaldor J.M., and Dore G.J. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 13 (2006) 34-41
3. Ishii S., and Koziel M.J. Immune responses during acute and chronic infection with hepatitis C virus. Clin Immunol 128 (2008) 133-147
4. Zeuzem S., Berg T., Moeller B., et al. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat 16 (2009) 75-90
5. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
6. Manns M.P., McHutchison J.G., Gordon S.C., et al., International Hepatitis Interventional Therapy Group. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
7. McHutchison J.G., Everson G.T., Gordon S.C., et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 360 (2009) 1827-1838
8. Lamarre D., Anderson P.C., Bailey M., et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426 (2003) 186-189
9. Reesink H.W., Zeuzem S., Weegink C.J., et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 131 (2006) 997-1002
10. Lawitz E., Rodriguez-Torres M., Muir A.J., et al. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol 49 (2008) 163-169
11. Sarrazin C., Rouzier R., Wagner F., et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon α-2b for genotype 1 nonresponders. Gastroenterology 132 (2007) 1270-1278
12. Raboisson P., Lin T.-I., de Kock H., et al. Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors. Bio Med Chem 18 (2008) 5095-5100
13. Lin T.-I., Devogelaere B., Lenz O., et al. Inhibitory activity of TMC435350 on HCV NS3/4A proteases from genotypes 1 to 6. Hepatology 48 (2008) 1166A
14. Lin T.-I., Lenz O., Fanning G., et al. In vitro activity and preclinical profile of TMC435350, a potent hepatitis c virus protease inhibitor. Antimicrobial Agents and Chemotherapy 53 (2009) 1377-1385
15. Dumont S., Fevery B., Van den Brande K., et al. Development of a platform to detect drug resistance mutations in the non-structural protein region of the hepatitis C virus genotypes 1, 2, 3 and 4. J Hepatol 50 (2009) S124
16. Neumann A.U., Lam N.P., Dahari H., et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 282 (1998) 103-107
17. Lenz O., Verbinnen T., Lin T.-I., et al. In vitro resistance profile of the HCV NS3/4A inhibitor TMC435350 (October 5-9, 2008) 15th International Symposium on HCV & Related Viruses, San Antonio, TX, USA
18. van 't Klooster G.A., Vanwelkenhuysen I., Verloes R., et al. Pharmacokinetics of once-daily regimens of the novel HCV NS3/4a-protease inhibitor TMC435350, with and without pegIFN and ribavirin, in HCV-infected individuals. Hepatology 48 (2008) 1158A
19. Reesink H., Verloes R., Abou Farha K., et al. Safety of the HCV protease inhibitor TMC435350 in healthy volunteers and safety and activity in chronic hepatitis C infected individuals: a phase I study. J Hepatol 48 (2008) S28-S29
20. Marcellin P., Reesink H., Berg T., et al. Antiviral activity and safety of TMC435 combined with peginterferon α-2a and ribavirin in patients with genotype 1 hepatitis C infection who failed previous IFN-based therapy. J Hepatol 50 (2009) S385
21. Manns M.P., Foster G.R., Rockstroh J.K., et al. The way forward in HCV treatment-finding the right path. Nat Rev Drug Discov 6 (2007) 991-1000
22. Kwo P., Lawitz E.J., McCone J., et al. HCV sprint-1: boceprevir plus peginterferon alfa-2b/ribavirin for treatment of genotype 1 chronic hepatitis C in previously untreated patients. Hepatology 48 (2008) 1027A